TrialSiteNews

UK Government denies lifesaving treatment for a 19-year-old woman. The Courts ruled in favor of a hospital who claims that the woman is incapable of making decisions about her future medical care because she is under the “delusion” that her death is not imminent. The unidentified woman has pleaded to be given a chance to live saying “This is my wish. I want to die trying to live. We have to try everything,” What in the world is happening in the UK?? ------------------------------------ Join The Conversation! | https://trialsitenews.com/

Alto Neuroscience announced the closing of a $35 million Series B financing, with participation from Novartis Pharma and other investors. This round brings Alto’s total funding to $75 million to date, and they will use the proceeds from the financing to advance lead candidates into Phase 2b studies in major depressive disorder in addition to continued development on other programs within its clinical-stage precision psychiatry pipeline.

Welcome to Investor Watch with James Ulrich. I’m your host, James, and in today’s episode, let’s talk about the next 2 million dollars that is being spent on fighting leukemia.

We don’t accept the status quo and we are doing something about it. The greenest borough with the largest produce market in the northeast United States can’t continue to be sickest county in the state. Healthy lifestyle is the best, cheapest and most effective healthcare for individuals, families, organizations and governments. Healthy Lifestyle is what we are all committed to educating our fellow New Yorkers on, especially our fellow Bronxites. These leaders renewed their commitment for the campaign this Saturday at Lincoln Hospital. Saving lives is the noblest cause to commit to. LIFESTYLE LIFESPAN! #healthylifestylemonth #not62 #lifestylelifespan

Cat Is Vaccine Injured. She received her first vaccine dose on April 2021 and began experiencing fatigue shortly afterwards. She saw a doctor about it, but didn't think it was related. Then, after receiving her booster shot on November 2021 her health rapidly declined. Cat has since tried raising awareness, but social media platforms have censored her efforts. She has received hate messages from those who don't believe her story and has had groups deleted. But she still isn't giving up. Find her here: https://www.facebook.com/groups/3217567388501402

125 million dollars is being waged in the war against diabetes, and this time it’s being sent to a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease: Provention Bio. They are looking to intervene by researching, developing, and bringing medicines to market that have the potential to help patients that would have otherwise robbed them of their full lifetime of potential. So far, they have deployed multiple candidates in conjunction with other organizations to combat these conditions. The best candidate? That would be Teplizumab.

Arcturus Therapeutics obtained a 63 million-dollar grant from the Biomedical Advanced Research and Development Authority (better known as the government program, BARDA). This will support the development of a self-amplifying mRNA vaccine for influenza. The award provides the funding over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus’ vaccine platform technology through Phase 1 clinical studies.

Windtree Therapeutics is advancing multiple late-stage interventions for acute cardiovascular and pulmonary syndromes to support patients. Their goal is to develop unique therapies that significantly improve upon the treatment of severe, acute conditions such as heart failure and lung injury.

This financing is to accelerate the development of new therapies to treat severe blood cancers and solid tumors, including further clinical development of the flagship project RVU120. RVU120 is a selective CDK8 kinase inhibitor in clinical development for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as solid tumors.

Summit Therapeutics announced topline results from the Phase III Ri-CoDIFy study evaluating ridinilazole for the treatment of and Sustained Clinical Response (SCR) for patients suffering from C. difficile infection (C. diff. infection or CDI). The study showed that ridinilazole resulted in a higher observed SCR rate than vancomycin but did not meet the study’s primary endpoint for superiority. SCR is defined as Clinical Response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment. Patients treated with ridinilazole experienced substantially less recurrence of C. diff. infection as compared to patients administered vancomycin. In this study recurrence was defined as a new episode of diarrhea (?3 unformed bowel movements) in a 1-day period with a positive C. difficile test that requires CDI antimicrobial treatment in subjects who achieved Clinical Response.

Iveric Bio has a drug in its pipeline that has the company excited for the future: Zimura. Zimura is an investigational complement C5 inhibitor that is designed to decrease the activation of inflammasomes and the formation of membrane attack complex (MAC). The company believes Zimura could treat Geographic Atrophy (GA) secondary to dry age-related macular degeneration (AMD) by preventing or slowing the degeneration of retinal pigment epithelial cells.

AstraZeneca is boosting its roster with the acquisition of TeneoTwo, which currently has a Phase 1 trial testing its newest treatment for blood cancer, in a deal valued up to 1.27 billion dollars. The transaction, expected to close in the third quarter of this year, includes TNB-486, which is part of a class of therapeutic antibodies called T-cell engagers. These are emerging as promising treatments for solid tumors and hematologic malignancies. The drug is also being considered for diffuse large B-cell lymphoma and follicular lymphoma. Bringing TeneoTwo into the fold allows Astrazeneca to build on the success of Calquence and further strengthen its pipeline.

Join The Conversation! | https://trialsitenews.com/ Neuron23, a biotech company focused on developing precision medicines for neurological and immunological diseases, has been receiving support from Westlake Village BioPartners and Kleiner Perkins for series A and B of drug development. However, as for the most recent round of funding, they got a huge boost from a reputable investor, the SoftBank Vision Fund. The SoftBank Vision Fund, a sub-category of SoftBank Group Corp., invested a whopping 100 million dollars into the series C, accounting for nearly half of the 213.5 million in total financing. With this funding, the young biotech company now plans for a clinical trial by the end of the year.

An enantiomer of Ketamine (R-Ketamine) has been approved by the United States Food and Drug Administration (FDA) for clinical trials in order to combat conditions like depression, treatment-resistant depression (TRD) in particular. Ketamine, a dissociative anesthetic developed in the 60’s, is primarily used for veterinary and human anesthesia. Sometimes its prescribed off-label, of course under medical supervision in a clinical setting, but if these trials underway provide convincing results, then R-ketamine could be a safe anti-depressant for people to use in their own homes.

FDA's Dr Peter Marks says the 4th Booster Dose was a "Stop-Gap" measure to buy time for the next booster.

A Purdue University spinoff project received a Small Business Innovation Research (S-B-I-R) Phase II grant for nearly 1 million dollars from the National Science Foundation to support the development of a proprietary biopolymer technology. The core technology, known as Collymer Self Assembling Scaffold (Collymer SAS), is a novel polymerizable collagen molecule that can be used to fabricate implantable materials to address reconstruction needs.

Join The Conversation! | https://trialsitenews.com/ Alexion, AstraZeneca’s rare diseases group, and Neurimmune announced the closing of an exclusive global collaboration and license agreement for NI006, an investigational human monoclonal antibody currently in phase 1b development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Alexion has been granted an exclusive worldwide license to develop, manufacture and commercialize NI006.

Join The Conversation! | https://trialsitenews.com/ While many people just assume biotech investors make big returns during the pandemic, perhaps nothing could be farther from the truth for many investors in this traditionally high volatile market. Recently, the Wall Street Journal reported that “The performance of the biotech sector this year is worse than all 11 of the S&P 500’s sectors.” Biotech stock prices overall have fallen after 2019 and 2020 surges. While some biotech and pharma companies were “winners,” most have missed out on the opportunity to monetize the pandemic. Looming questions and issues mount—spooking potential investors—which, of course, can adversely impact share prices. Do some noticeable losses in hedge funds introduce more risk or opportunity?

Join The Conversation! | https://trialsitenews.com/ While many people just assume biotech investors make big returns during the pandemic, perhaps nothing could be farther from the truth for many investors in this traditionally high volatile market. Recently, the Wall Street Journal reported that “The performance of the biotech sector this year is worse than all 11 of the S&P 500’s sectors.” Biotech stock prices overall have fallen after 2019 and 2020 surges. While some biotech and pharma companies were “winners,” most have missed out on the opportunity to monetize the pandemic. Looming questions and issues mount—spooking potential investors—which, of course, can adversely impact share prices. Do some noticeable losses in hedge funds introduce more risk or opportunity?

Join The Conversation! | https://trialsitenews.com/ We are thrilled to announce the release of the new TrialSite app. With over 70% of people reading TrialSite News from a mobile device, this is an important next step in our goal of connecting the clinical research community around the globe. Features of the app: Latest news and analysis of clinical research Enhanced commenting and usability Groups, forums and discussions Connection with other community members The app is free to download and is available for both IOS and Android phones. iOS App Link: https://apps.apple.com/us/app/trialsite/id1565856630 Google Play Link: https://play.google.com/store/apps/details?id=com.trialsitenews.trialsite